Universitatsmedizin Mannheim | II.Medizinischen Klinik
Status and phase
Conditions
Treatments
About
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome [ASyS]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Additional information can be found on https://myositis-study.com/.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The full list of inclusion criteria can be found in the protocol.
Exclusion criteria
The full list of exclusion criteria can be found in the protocol.
Primary purpose
Allocation
Interventional model
Masking
240 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Sabine Coppieters, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal